On receptor inhibitors and chemotherapy

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4607-4609

  Ryan, P D ^a   Chabner, B A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; EDITORIAL; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAENORHABDITIS ELEGANS PROTEINS; HELMINTH PROTEINS; HUMANS; LIGANDS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0034486406     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
2. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
3. Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and progress
4. The epidermal growth factor receptor and the prognosis of bladder cancer
5. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
6. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
7. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), shows evidence of good tolerability and activity: Final results from a Phase I study
8. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (IRESSA™), an inhibitor of EGFR tyrosine kinase
9. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
10. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
11. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
12. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled Phase III trial
13. Phase I study of chimerized anti-epidermal growth factor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
14. Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
15. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis
16. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
17. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts
18. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
19. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts
20. cdc2kinase
21. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
22. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic-AMP-dependent protein kinase
23. Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications
24. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor receptor antibody on human breast cancer cell growth
25. ZD 1839, an epidermal growth factor receptor tyrosine kinase inhibitor selected for clinical development
26. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor
27. CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against head and neck tumor cells
28. Neutalizing antibodies to EGF and ErbB2/neu receptor tyrosine kinases down-regulate VEGF production in tumor cells in vitro and in vivo: Angiogenic implications for transduction therapy of solid tumors
29. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice